Last reviewed · How we verify

SGLT2 inhibitor, GLP-1 RA

Brigham and Women's Hospital · FDA-approved active Small molecule

This dual-action drug combines SGLT2 inhibition (reducing glucose reabsorption in the kidney) with GLP-1 receptor agonism (enhancing insulin secretion and satiety) to lower blood glucose and body weight.

This dual-action drug combines SGLT2 inhibition (reducing glucose reabsorption in the kidney) with GLP-1 receptor agonism (enhancing insulin secretion and satiety) to lower blood glucose and body weight. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in type 2 diabetes.

At a glance

Generic nameSGLT2 inhibitor, GLP-1 RA
SponsorBrigham and Women's Hospital
Drug classSGLT2 inhibitor / GLP-1 receptor agonist combination
TargetSGLT2 and GLP-1R
ModalitySmall molecule
Therapeutic areaDiabetes, Cardiovascular
PhaseFDA-approved

Mechanism of action

SGLT2 inhibitors block sodium-glucose cotransporter 2 in the proximal tubule, promoting urinary glucose excretion independent of insulin. GLP-1 receptor agonists activate GLP-1 receptors on pancreatic beta cells and in the brain, stimulating glucose-dependent insulin secretion and reducing appetite. The combination provides complementary glucose-lowering and weight-loss effects with potential cardiovascular and renal benefits.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: